INTS

Intensity Therapeutics, Inc. - Common Stock (INTS)

About Intensity Therapeutics, Inc. - Common Stock (INTS)

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Details

Daily high

$1.94

Daily low

$1.80

Price at open

$1.83

52 Week High

$5.28

52 Week Low

$1.50

Market cap

28.1M

Dividend yield

0.00%

Volume

7,390

Avg. volume

15,680

P/E ratio

-1.58

Intensity Therapeutics, Inc. - Common Stock News